Lab Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Argos Therapeutics
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
November 8th, 2009
Argos Therapeutics announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. The presentations contained important results, including a favorable safety profile for AGS-004, the ability to induce partial to complete viral load control in the absence of antiretroviral therapy (ART) during a 12-week structured treatment interruption (STI),...
Source: Lab Business Week (2009-11-08)
|
